Evista
Evista, known generically as raloxifene, is primarily used for preventing and treating osteoporosis in postmenopausal women. As a selective estrogen receptor modulator (SERM), it mimics estrogen’s positive effects on bone density, reducing fracture risk and enhancing skeletal health. Evista also lowers the risk of invasive breast cancer in postmenopausal women with osteoporosis or high breast cancer risk, offering multifaceted benefits. Consulting healthcare providers ensures suitability and addresses potential side effects for users effectively.

